CytomX Therapeutics, Inc. announced that the Company presented data characterizing the preclinical profile of its EpCAM-targeting ADC, CX-2051, at the World ADC conference taking place October 16-19, 2023, in San Diego, CA. "CX-2051 is designed to address the unmet needs of patients with EpCAM-expressing tumors, including colorectal cancer, where EpCAM expression is uniformly high. EpCAM is a broadly expressed, validated anti-cancer target that to date has been limited in its development potential due to systemic, on-target off-tumor dose-limiting toxicities".
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.905 USD | -6.62% | -56.43% | +24.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.52% | 138M | |
+3.27% | 108B | |
+10.42% | 104B | |
+0.41% | 22.33B | |
-11.68% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-8.84% | 17.64B | |
+6.76% | 14.05B | |
+36.78% | 12.51B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference